Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06615024
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-24
Brief Title:
Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Newborn Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency in NEW VALLEY GOVERNORATE
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
G6PD deficiency may have a subtle effect on the severity of hemolysis and also worsen the degree of anaemia in SCD when the two disorders coexist Therefore selective decision should be taken in patients in whom the two conditions coexist in the choice of drug and in the treatment of infectionsThe prevalence of the G-6-PD deficiency is high in SCD patients but does not differ from that observed among non-SCD subjects However the G-6-PD deficiency appears to worsen the clinical features of SCD there were more hospitalizations major vaso-occlusive crises among G-6-PD deficient sickle cell patients
Detailed Description:
Sickle cell disease SCD is not frequent in Egypt except in the Oases where the carrier rate varies from 9 to 22 It is a hereditary blood disorder characterized by the production of abnormal hemoglobin molecules that cause red blood cells to take on a crescent or sickle shape This haemoglobin called haemoglobin S which causes red blood cells to become stiff and sticky leading to various health complications as recurrent pain fatigue anaemia and increased infection susceptibilityprevalence of G6PD deficiency is 43 with a malefemale ratio of 321 Enzyme activity was significantly higher in males than females It is located on X chromosome which leads to a lower level of reduced glutathione an antioxidant in red blood cells RBCs Most of the time those who are affected have no symptoms However they should avoid specific triggers that may promote oxidative stress such as fava beans that may fragilize RBCs and cause hemolysis G6PD deficiency may have a subtle effect on the severity of hemolysis and also worsen the degree of anaemia in SCD when the two disorders coexist Therefore selective decision should be taken in patients in whom the two conditions coexist in the choice of drug and in the treatment of infections The prevalence of the G-6-PD deficiency is high in SCD patients but does not differ from that observed among non-SCD subjects However the G-6-PD deficiency appears to worsen the clinical features of SCD there were more hospitalizations major vaso-occlusive crises among G-6-PD deficient sickle cell patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None